Capricor Therapeutics, Inc., a clinical-stage biotechnology company, has been actively engaged in the development and commercialization of biological therapies aimed at treating Duchenne muscular dystrophy (DMD) and other rare disorders. Operating primarily within the healthcare sector, the company is headquartered in Beverly Hills, United States, and extends its services to both the US and Canada.
As of September 9, 2026, Capricor Therapeutics’ stock was trading at a close price of $8.3 on the Nasdaq exchange. The company’s market capitalization stood at approximately $502.32 million. Over the past year, the stock has experienced significant volatility, with a 52-week high of $40.37 recorded on December 2, 2025, and a 52-week low of $2.96 on July 29, 2026. This fluctuation reflects the dynamic nature of the biotechnology sector and the challenges inherent in developing therapies for rare diseases.
The company’s financial metrics indicate a price-to-earnings (P/E) ratio of -3.53, suggesting that it is not currently generating profits. This is not uncommon for companies in the clinical stage of drug development, where substantial investments in research and development are prioritized over immediate profitability.
Capricor Therapeutics’ focus on Duchenne muscular dystrophy, a rare genetic disorder characterized by progressive muscle degeneration and weakness, underscores its commitment to addressing unmet medical needs. The company’s efforts are directed towards advancing its pipeline of biological therapies, which hold the potential to significantly impact the lives of patients suffering from DMD and other similar conditions.
For stakeholders and interested parties seeking further information about Capricor Therapeutics’ activities, offerings, and strategic initiatives, the company maintains an online presence through its website at www.capricor.com . Here, updates on clinical trials, partnerships, and other developments are regularly posted, providing transparency and insight into the company’s progress and future directions.
In summary, Capricor Therapeutics, Inc. remains a key player in the biotechnology landscape, with a clear focus on developing innovative therapies for rare diseases. Despite the financial challenges typical of the industry, the company’s dedication to its mission continues to drive its efforts in the healthcare sector.
